Key result
Heart Team evaluation guides appropriate patient selection for MitraClip in mitral regurgitation.
Why the study?
The MitraClip is the first-in-class percutaneous therapy for mitral regurgitation with limited regional experience and clinical indication data in Singapore since 2011.
Supports Heart Team-guided MitraClip use in selected patients; leaves open long-term regional efficacy data.
The MitraClip is the first-in-class percutaneous therapy for mitral regurgitation. It is delivered from the femoral vein and can be used for degenerative or functional mitral regurgitation. In Singapore, the device was first approved for use in 2011. This review describes the device and discusses the data supporting its use and the regional experience to date. The MitraClip, given the early experience, should only be used after consideration by Heart Teams and only in appropriately selected patients.
No takes yet. Share an insight, caveat, or question.
Khung Keong Yeo (2015) conducted a review in Mitral regurgitation. MitraClip was evaluated. The MitraClip percutaneous therapy for degenerative or functional mitral regurgitation should be utilized only after Heart Team consideration in appropriately selected patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: